SCHEMBL6501476

SCHEMBL6501476

COc1cc2c(Nc3cc(C(C)C(=O)O)n[nH]3)ncnc2cc1OCCCN1CCOCC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 10/20 0.60
KDR P35968 9/20 0.60
AURKA O14965 7/20 0.60
SRC P12931 6/20 0.60
AURKB Q96GD4 3/20 0.60
LCK P06239 2/20 0.60
RET P07949 2/20 0.60
MET P08581 2/20 0.60
MAPT P10636 2/20 0.60
LTK P29376 2/20 0.60
TNK2 Q07912 2/20 0.60
MAP4K5 Q9Y4K4 2/20 0.60
ROCK2 O75116 1/20 0.60
ALDH1A1 P00352 1/20 0.60
FYN P06241 1/20 0.60
PDGFRA P16234 1/20 0.60
TTK P33981 1/20 0.60
MAP2K2 P36507 1/20 0.60
MAP2K1 Q02750 1/20 0.60
BTK Q06187 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6495649 0.86 KDR (0.49) EGFRKDR
SCHEMBL4289349 0.86 EGFR (0.62) EGFRKDRAURKASRCAURKB
SCHEMBL13749953 0.85 SRC (0.62) EGFRKDRAURKASRCAURKB
SCHEMBL4414825 0.85 SRC (0.62) EGFRKDRAURKASRCAURKB
SCHEMBL13750138 0.83 SRC (0.66) EGFRKDRAURKASRCLCK
SCHEMBL5653890 0.79 AURKA (0.75) EGFRKDRAURKASRCAURKB
SCHEMBL5025344 0.78 AURKA (0.64) EGFRKDRAURKASRCAURKB
SCHEMBL14421400 0.78 SRC (0.68) EGFRKDRAURKASRCAURKB
SCHEMBL14421402 0.78 AURKA (0.64) EGFRKDRAURKASRCAURKB
SCHEMBL28350783 0.78 SRC (0.73) EGFRKDRAURKASRCLCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050070561-A1 Substituted quinazoline derivatives as inhibitors of aurora kinases ASTRAZENECA AB (SE) 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070561-A1 Substituted quinazoline derivatives as inhibitors of aurora kinases AURKC, AURKA, AURKB EGFR 1016/4885KDR 933/4885AURKA 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.